The FDA granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer.
The Centers for Medicare & Medicaid Services issued a second interim final rule, which established new regulatory waivers and rule changes to increase flexibility for healthcare providers during the COVID-19 pandemic.
Researchers in New York City reported a significant increase in case fatality in patients with cancer and COVID-19 compared with patients with COVID-19 who did not have cancer.
In this systematic review, researchers highlighted the strengths and weaknesses of existing decision aids for women with an average risk of breast cancer who are eligible for mammographic screening.
The results from this random-effects meta-analysis suggested that dietary fiber intake may decrease the risk of breast cancer, including both premenopausal and postmenopausal breast cancers.
Researchers demonstrated that risk models that include established clinical, genetic, and circulating factors are better able to identify people at significantly higher than normal risk of pancreatic cancer over those using clinical factors alone.
In a webinar, a multidisciplinary team from Duke Cancer Center came together to discuss the differences in treating patients with genitourinary cancer as a result of the COVID-19 pandemic.
A recent study led by led by King's College London and Public Health England examined 1.4 million patients of cancer via the National Cancer Registry and found that early GP referrals led to longer survival rates for patients.
This data analysis suggested that larotrectinib is highly effective in patients with NTRK gene fusions, however offered minimal benefit in patients with other non-fusion NTRK alterations.
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.